36 results match your criteria: "Hospital Vito Fazzi[Affiliation]"
Med Phys
February 2019
Department of Medical Physics, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, 70124, Italy.
Introduction: Before the approval of any Intensity Modulated Radiation Therapy or Volumetric Modulated Arc Therapy treatment plan, quality assurance (QA) tests are needed to reveal potential errors such as an inaccurate calculation of the dose distribution, the failure of the record-and-verify system, or the delivery system of the linear accelerator. Currently, the method adopted to compare the measured dose distribution with the treatment planning system TPS calculated dose distribution is gamma analysis. However, gamma analysis has been shown to be ineffective for the clinical evaluation of treatment plans.
View Article and Find Full Text PDFAnn Hematol
October 2018
Department of Hematology, Hospital University Riuniti, Foggia, Italy.
Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV.
View Article and Find Full Text PDFAnn Oncol
January 2018
Medical Oncology, Department of Clinical and Experimental Medicine "F. Magrassi, " Università della Campania "L. Vanvitelli," Napoli, Italy.
Background: Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line anti-EGFR monoclonal antibody-based therapy.
Patients And Methods: In the CAPRI-GOIM trial, 340 KRAS exon-2 wild-type mCRC patients received first-line cetuximab plus FOLFIRI.
Eur Ann Allergy Clin Immunol
May 2015
Section of Allergology and Clinical Immunology, Department of Internal Medicine and Infectious Diseases, University of Bari Medical School, Bari, Italy. Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Allergic reactions to mannitol have been reported rarely, despite its widespread use as a drug and as a food excipient. This is the first case report in which oral mannitol induces an immediate type hypersensitivity as a drug excipient, in a 42 year old man affected by rhinitis to olive tree pollen. Unusual and undervalued risk factors for mannitol hypersensitivity are examined.
View Article and Find Full Text PDFInt J Dent
June 2014
UO Odontoiatria (Istituto Giannina Gaslini), Private Practice, Via Fontevivo 21N, 19125 La Spezia, Italy.
Aim. The aim of this study is to compare dental and skeletal effects produced by an acrylic splint Herbst with and without skeletal anchorage for correction of dental class II malocclusion. Methods.
View Article and Find Full Text PDFInt J Mol Sci
September 2013
Medical Oncology Unit, Hospital Vito Fazzi, Lecce 73100, Italy.
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with time and lead cancer cells not only to survive, but also to invade the surrounding tissues and metastasise to distant sites. These changes include: genetic alterations in oncogenes and cancer suppressor genes; changes in the cell cycle and pathways leading to apoptosis; and also changes in epithelial to mesenchymal transition. The most common alterations involve the epidermal growth factor receptor (EGFR) gene, the HER2 gene, and the K-ras gene.
View Article and Find Full Text PDFJ Chemother
February 2012
Hospital Vito Fazzi, ENT Division, Lecce, Italy.
The aim of this study was to assess the concentration of ulifloxacin, the active metabolite of prulifloxacin, in sinuses mucosa and plasma of patients with chronic rhinosinusitis, requiring sinus elective endoscopic surgery. Thirty-nine patients (30 males, 9 females; age range 22-77 years) with chronic sinusitis were enrolled, 35 were treated with the investigational medication. Samples from four untreated patients were used to validate the analytical method, while four treated patients dropped out before surgery.
View Article and Find Full Text PDFFront Biosci (Schol Ed)
January 2012
Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy.
EGFR and HER2 are highly expressed in 15-30% of breast cancer tissues. Therefore, EGFR and its downstream signaling pathways are promising anti-tumour targets. HER2 overexpression is often associated with estrogen receptor (ER) and progesterone receptor (PR) negativity, high histological grade, high rates of cell proliferation and lymph node involvement.
View Article and Find Full Text PDFCurr Drug Targets
April 2011
Medical Oncology Unit, Hospital Vito Fazzi, Lecce, Italy.
Dasatinib (BMS-354825, Sprycel®) is an oral, multitargeted inhibitor of receptor tyrosine kinases (RTKs), including BCR-ABL fusion protein, stem cell factor receptor (c-KIT), platelet-derived growth factor receptor (PDGFR), and Src family kinases (SFKs). Several early- and late-phase clinical trials for chronic myelogeneous leukaemia (CML) have demonstrated the direct inhibition of BCR-ABL fusion protein and SFKs, which led to dasatinib approval by the Food and Drug Administration (FDA) and the European Union for the treatment of imatinib-resistant or -intolerant CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Phase III dose-optimization study was performed to compare different regimens, stating that dasatinib 100 mg once daily is now the recommended schedule for patients with chronic CML, and 140 mg once daily for patients with accelerated phase or myeloid or lymphoid blast phase CML, and for patients with Ph+ ALL until progression.
View Article and Find Full Text PDFContact Dermatitis
September 2008
Allergy and Clinical Immunology Center, Civil Hospital Vito Fazzi, 73100 Lecce, Italy.
Br J Haematol
April 2005
Section of Medical Oncology, Hospital Vito Fazzi, Lecce.
Bone marrow endothelial cells (EC) from patients with multiple myeloma (MM) were found to express and secrete higher amounts of the CXC-chemokines CXCL8/interleukin (IL)-8, CXCL11/interferon-inducible T-cell alpha chemoattractant (I-TAC), CXCL12/stromal cell-derived factor (SDF)-1alpha, and CCL2/monocyte chemotactic protein(MCP)-1 than EC from human umbilical vein (HUVEC), considered as a healthy counterpart. Paired plasma cells and several MM cell lines expressed cognate receptors of each chemokine to a variable extent. When cells were exposed to chemokines, CXCL8/IL-8 and CXCL12/SDF-1alpha stimulated their proliferation and all chemokines stimulated cell chemotaxis.
View Article and Find Full Text PDF